|
Name |
4-Epi-seco-shornephine a carboxylic acid
|
Molecular Formula | C25H28N2O6 | |
IUPAC Name* |
(2R)-3-[(3R)-7-hydroxy-3-(2-methylbut-3-en-2-yl)-2-oxo-1H-indol-3-yl]-2-[[(2S)-2-hydroxy-3-phenylpropanoyl]amino]propanoic acid
|
|
SMILES |
CC(C)(C=C)[C@@]1(C2=C(C(=CC=C2)O)NC1=O)C[C@H](C(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)O
|
|
InChI |
InChI=1S/C25H28N2O6/c1-4-24(2,3)25(16-11-8-12-18(28)20(16)27-23(25)33)14-17(22(31)32)26-21(30)19(29)13-15-9-6-5-7-10-15/h4-12,17,19,28-29H,1,13-14H2,2-3H3,(H,26,30)(H,27,33)(H,31,32)/t17-,19+,25-/m1/s1
|
|
InChIKey |
TXVLBRMNUYNGCT-VDABOFBKSA-N
|
|
Synonyms |
4-epi-seco-shornephine a carboxylic acid
|
|
CAS | NA | |
PubChem CID | 156580567 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 452.5 | ALogp: | 2.9 |
HBD: | 5 | HBA: | 6 |
Rotatable Bonds: | 9 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 136.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 33 | QED Weighted: | 0.293 |
Caco-2 Permeability: | -5.848 | MDCK Permeability: | 0.00001530 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.014 |
Human Intestinal Absorption (HIA): | 0.214 | 20% Bioavailability (F20%): | 0.847 |
30% Bioavailability (F30%): | 0.008 |
Blood-Brain-Barrier Penetration (BBB): | 0.036 | Plasma Protein Binding (PPB): | 96.86% |
Volume Distribution (VD): | 0.163 | Fu: | 3.55% |
CYP1A2-inhibitor: | 0.012 | CYP1A2-substrate: | 0.086 |
CYP2C19-inhibitor: | 0.041 | CYP2C19-substrate: | 0.194 |
CYP2C9-inhibitor: | 0.263 | CYP2C9-substrate: | 0.971 |
CYP2D6-inhibitor: | 0.01 | CYP2D6-substrate: | 0.179 |
CYP3A4-inhibitor: | 0.121 | CYP3A4-substrate: | 0.418 |
Clearance (CL): | 0.575 | Half-life (T1/2): | 0.86 |
hERG Blockers: | 0.028 | Human Hepatotoxicity (H-HT): | 0.182 |
Drug-inuced Liver Injury (DILI): | 0.736 | AMES Toxicity: | 0.024 |
Rat Oral Acute Toxicity: | 0.819 | Maximum Recommended Daily Dose: | 0.041 |
Skin Sensitization: | 0.038 | Carcinogencity: | 0.034 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.007 |
Respiratory Toxicity: | 0.049 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004262 | 0.867 | D0RA5Q | 0.393 | ||||
ENC001985 | 0.432 | D0D7KC | 0.351 | ||||
ENC004235 | 0.417 | D0A8XN | 0.331 | ||||
ENC001904 | 0.382 | D0L0SW | 0.326 | ||||
ENC000717 | 0.365 | D0SH3I | 0.323 | ||||
ENC003221 | 0.344 | D0BV3J | 0.322 | ||||
ENC003246 | 0.344 | D06PSS | 0.316 | ||||
ENC004494 | 0.333 | D02NEH | 0.313 | ||||
ENC005251 | 0.333 | D0W9WF | 0.312 | ||||
ENC004607 | 0.331 | D0Y0JH | 0.312 |